{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:20:26Z","timestamp":1791321626881,"version":"4.3.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.forsciint.2023.111775","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T03:40:44Z","timestamp":1687923644000},"page":"111775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Non-fentanyl new synthetic opioids \u2013 An update"],"prefix":"10.1016","volume":"349","author":[{"given":"Jolanta B.","family":"Zawilska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Adamowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kurpeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Wojcieszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.forsciint.2023.111775_bib1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, New psychoactive substances: 25 years of early warning and response in Europe, \u3008https:\/\/www.emcdda.europa.eu\/publications\/poster\/eu-early-warning-system-nps-25-years_en\u3009, 2022 (Accessed 13 November 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib2","unstructured":"United Nations Office on Drugs and Crime, World Drug Report 2022. Booklet 4 - Drug market trends of Cocaine, Amphetamine-type stimulants and New Psychoactive Substances, \u3008https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2022.html\u3009, 2022 (Accessed 29 October 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib3","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1093\/jat\/bkac023","article-title":"Reports of adverse events associated with use of novel psychoactive substances, 2017-2020","volume":"46","author":"Mohr","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320967197","article-title":"New psychoactive substances: a review and updates","volume":"10","author":"Shafi","year":"2020","journal-title":"Ther. Adv. Psychopharmac"},{"key":"10.1016\/j.forsciint.2023.111775_bib6","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, European Drug Report 2022: Trends and Development, \u3008https:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2022_en\u3009, 2022 (Accessed 3 October 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/20961790.2019.1588933","article-title":"Novel synthetic opioids - toxicological aspects and analysis","volume":"4","author":"Tabarra","year":"2019","journal-title":"Forensic Sci. Res"},{"key":"10.1016\/j.forsciint.2023.111775_bib8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","article-title":"DARK classics in chemical neuroscience: etonitazene and related benzimidazoles","volume":"12","author":"Ujv\u00e1ry","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.forsciint.2023.111775_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fpsyt.2017.00110","article-title":"An expanding world of novel psychoactive substances: opioids","volume":"8","author":"Zawilska","year":"2017","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.forsciint.2023.111775_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PAF.0000000000000787","article-title":"Proliferation of novel synthetic opioids in postmortem investigations after core-structure scheduling for fentanyl-related substances","volume":"43","author":"Papsun","year":"2022","journal-title":"Am. J. Forensic Med. Path"},{"key":"10.1016\/j.forsciint.2023.111775_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(19)30218-4","article-title":"Control of fentanyl-related substances in China","volume":"6","author":"Bao","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.forsciint.2023.111775_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/dta.2738","article-title":"Report on a novel emerging class of highly potent benzimidazole NPS opioids: chemical and in vitro functional characterization of isotonitazene","volume":"12","author":"Blanckaert","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-018-0454-5","article-title":"The search for the \"next\" euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning","volume":"37","author":"Sharma","year":"2019","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11419-022-00624-y","article-title":"Non-fentanyl-derived synthetic opioids emerging during recent years","volume":"40","author":"Hasegawa","year":"2022","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.forsciint.2023.111775_bib17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/jat\/bkaa115","article-title":"A 2017-2019 update on acute intoxications and fatalities from illicit fentanyl and analogs","volume":"4","author":"Brunetti","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1373\/clinchem.2017.281626","article-title":"The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union","volume":"65","author":"Jannetto","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.forsciint.2023.111775_bib19","first-page":"105","article-title":"Comparative study of 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine and its enantiomorphs on analgesic and other pharmacological activities in experimental animals","volume":"221","author":"Nakamura","year":"1976","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.forsciint.2023.111775_bib20","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, MT-45: report on the risk assessment of MT-45 in the framework of the Council Decision on new psychoactive substances, \u3008https:\/\/www.emcdda.europa.eu\/publications\/risk-assessments\/mt-45_en\u3009, 2015 (Accessed 2 November 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11419-013-0194-5","volume":"32","author":"Uchiyama","year":"2014","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/15563650.2014.943908","article-title":"MT-45, a new psychoactive substance associated with hearing loss and unconsciousness","volume":"52","author":"Helander","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/jat\/bkx058","article-title":"Identification of MT-45 metabolites: in silico prediction, in vitro incubation with rat hepatocytes and in vivo confirmation","volume":"41","author":"Montesano","year":"2017","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0014-2999(84)90722-2","article-title":"Central actions of AD-1211, an analgesic lacking common opiate features","volume":"106","author":"Nakamura","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.forsciint.2023.111775_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jat\/bkaa066","article-title":"Report on a new opioid NPS: chemical and in vitro functional characterization of a structural isomer of the MT-45 derivative diphenpipenol","volume":"45","author":"Cannaert","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib27","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1021\/acschemneuro.1c00522","article-title":"DARK classics in chemical neuroscience: bucinnazine","volume":"12","author":"Resnik","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.forsciint.2023.111775_bib28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00204-022-03257-7","article-title":"Toxicological and pharmacological characterization of novel cinnamylpiperazine synthetic opioids in humans and in vitro including 2-methyl AP-237 and AP-238","volume":"96","author":"Fogarty","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00204-021-03207-9","article-title":"Characterization of recent non-fentanyl synthetic opioids via three different in vitro \u00b5-opioid receptor activation assays","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11419-015-0271-z","article-title":"AH-7921: the list of new psychoactive opioids is expanded","volume":"33","author":"Katselou","year":"2015","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib31","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, Report on the risk assessment of 3,4-dichloro N-{[1-(dimethylamino)cyclohexyl]methyl} benzamide (AH-7921) in the framework of the Council Decision on new psychoactive substances, \u3008https:\/\/www.emcdda.europa.eu\/publications\/risk-assessment\/AH-7921_en\u3009, 2014 (Accessed 2 November 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jat\/bku057","article-title":"Fatal intoxications associated with the designer opioid AH-7921","volume":"38","author":"Kronstrand","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/dta.1856","article-title":"Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation","volume":"8","author":"Wohlfarth","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/brainsci10110895","article-title":"U-47700 and its analogs: non-fentanyl synthetic opioids impacting the recreational drug market","volume":"10","author":"Baumann","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.forsciint.2023.111775_bib35","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/jat\/bkx081","article-title":"U-47700: a not so new opioid","volume":"42","author":"Rohrig","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib37","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1021\/acschemneuro.0c00330","article-title":"DARK classics in chemical neuroscience: U-47700","volume":"11","author":"Kyei-Baffour","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.forsciint.2023.111775_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11419-016-0347-4","article-title":"U-47700. An old opioid becomes a recent danger","volume":"35","author":"Nikolaou","year":"2017","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib39","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1038\/s41598-017-06778-9","article-title":"Updating the list of known opioids through identification and characterization of the new opioid derivative 3,4-dichloro-N-(2-(diethylamino)cyclohexyl)-N-methylbenzamide (U-49900)","volume":"7","author":"Fabregat-Safont","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.forsciint.2023.111775_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109292","article-title":"Characteristics of fatal 'novel' synthetic opioid toxicity in Australia","volume":"232","author":"Darke","year":"2022","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.forsciint.2023.111775_bib41","first-page":"1119","article-title":"Notes from the Field: Counterfeit Percocet-Related Overdose Cluster - Georgia, June 2017","volume":"66","author":"Edison","year":"2017"},{"key":"10.1016\/j.forsciint.2023.111775_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00414-021-02729-2","article-title":"Blood concentrations of new synthetic opioids","volume":"136","author":"Adamowicz","year":"2022","journal-title":"Int. J. Leg. Med"},{"key":"10.1016\/j.forsciint.2023.111775_bib43","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.forsciint.2019.04.010","article-title":"Postmortem concentrations of the synthetic opioid U-47700 in 26 fatalities associated with the drug","volume":"301","author":"Fels","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2023.111775_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2019.109999","article-title":"Distribution of synthetic opioids in postmortem blood, vitreous humor and brain","volume":"305","author":"Chesser","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2023.111775_bib45","article-title":"On the horizon: the synthetic opioid U-49900","volume":"9","author":"Alzghari","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.forsciint.2023.111775_bib46","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/dta.3238","article-title":"Investigation of the \u03bc- and \u03ba-opioid receptor activation by eight new synthetic opioids using the [35S]-GTP\u03b3S assay: U-47700, isopropyl U-47700, U-49900, U-47931E, N-methyl U-47931E, U-51754, U-48520, and U-48800","volume":"14","author":"Otte","year":"2022","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib47","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/dta.2683","article-title":"Toxicokinetics and analytical toxicology of the abused opioid U-48800 - in vitro metabolism, metabolic stability, isozyme mapping, and plasma protein binding","volume":"11","author":"Gampfer","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/15563650.2016.1209767","article-title":"A case of U-47700 overdose with laboratory confirmation and metabolite identification","volume":"55","author":"Jones","year":"2017","journal-title":"Clin. Toxicol. (Philos. )"},{"key":"10.1016\/j.forsciint.2023.111775_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/dta.2228","article-title":"Metabolism of novel opioid agonists U-47700 and U-49900 using human liver microsomes with confirmation in authentic urine specimens from drug users","volume":"10","author":"Krotulski","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib50","doi-asserted-by":"crossref","first-page":"13774","DOI":"10.1038\/s41598-019-50196-y","article-title":"Studies on the in vitro and in vivo metabolism of the synthetic opioids U-51754, U-47931E, and methoxyacetylfentanyl using hyphenated high-resolution mass spectrometry","volume":"9","author":"Nordmeier","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.forsciint.2023.111775_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00414-018-1969-3","article-title":"Case report: relevance of metabolite identification to detect new synthetic opioid intoxications illustrated by U-47700","volume":"133","author":"Richeval","year":"2019","journal-title":"Int. J. Leg. Med"},{"key":"10.1016\/j.forsciint.2023.111775_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchromb.2019.02.026","article-title":"Quantification of U-47700 and its metabolites in plasma by LC-MS\/MS","volume":"1112","author":"Smith","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.forsciint.2023.111775_bib53","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920\/2006 (as amended), \u3008https:\/\/www.emcdda.europa.eu\/publications\/risk-assessments\/isotonitazene_en\u3009, 2020 (Accessed 26 September 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib54","first-page":"bkab082","article-title":"The rise and fall of isotonitazene and brorphine: two Recent stars in the synthetic opioid firmament","author":"Vandeputte","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib55","unstructured":"United Nations Office on Drugs and Crime, CND Decision on international control of isotonitazene enters into force, \u3008https:\/\/www.unodc.org\/LSS\/announcement\/Details\/65247392\u201326c7\u2013446-a2b6\u2013270226103036\u3009, 2021(Access 10 November 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib56","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.15585\/mmwr.mm7137a5","article-title":"Notes from the field: nitazene-related deaths - tennessee, 2019-2021","volume":"71","author":"Roberts","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.forsciint.2023.111775_bib57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jat\/bkab117","article-title":"A forward-thinking approach to addressing the new synthetic opioid 2-benzylbenzimidazole nitazene analogs by liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS)","volume":"46","author":"Walton","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/dta.3440","article-title":"Rapid screening of 2-benzylbenzimidazole nitazene analogs in suspect counterfeit tablets using Raman, SERS, DART-TD-MS, and FT-IR","volume":"15","author":"Kimani","year":"2023","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib59","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u03bc-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.forsciint.2023.111775_bib60","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00204-022-03276-4","article-title":"Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole \u2018nitazene\u2019 synthetic opioid","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib61","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/dta.3377","article-title":"Identification of etazene (etodesnitazene) metabolites in human urine by LC-HRMS","volume":"15","author":"Verougstraete","year":"2023","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109263","article-title":"Pharmacological characterization of novel synthetic opioids: Isotonitazene, metonitazene, and piperidylthiambutene as potent \u03bc-opioid receptor agonists","volume":"221","author":"De Luca","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.forsciint.2023.111775_bib64","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jat\/bkaa016","article-title":"Isotonitazene quantitation and metabolite discovery in authentic forensic casework","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib66","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/dta.3115","article-title":"Metonitazene in the United States \u2013 forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry","volume":"13","author":"Krotulski","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib68","unstructured":"Department of Health, Victoria, Australia, Pronitazene sold as ketamine. \u3008https:\/\/www.health.vic.gov.au\/drug-alerts\/yellow-powder-containing-protonitazene-may-be-sold-as-ketamine\u3009, 2022 (Accessed 16 November 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib69","first-page":"bkac062","article-title":"Intoxications in an Australian emergency department involving 'nitazene' benzylbenzimidazole synthetic opioids (etodesnitazene, butonitazene and protonitazene)","volume":"19","author":"Schumann","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib70","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00204-022-03294-2","article-title":"First identification, chemical analysis and pharmacological characterization of N-piperidinyl etonitazene (etonitazepipne), a recent addition to the 2-benzylbenzimidazole opioid subclass","volume":"96","author":"Vandeputte","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib72","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/15563650.2022.2084406","article-title":"Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose","volume":"60","author":"Calello","year":"2022","journal-title":"Clin. Toxicol. (Philos. )"},{"key":"10.1016\/j.forsciint.2023.111775_bib73","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/15563650.2021.1979235","article-title":"Severe toxicity involving N-pyrrolidino etonitazene in the United Kingdom \u2013 a case report","volume":"60","author":"Pucci","year":"2022","journal-title":"Clin. Toxicol. (Philos. )"},{"key":"10.1016\/j.forsciint.2023.111775_bib74","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1007\/s00204-020-02855-7","article-title":"In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances","volume":"94","author":"Vandeputte","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110989","article-title":"Pharmacological and metabolic characterization of the novel synthetic opioid brorphine and its detection in routine casework","volume":"327","author":"Grafinger","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2023.111775_bib77","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/jat\/bkaa094","article-title":"First report on brorphine: the next opioid on the deadly new psychoactive substance horizon?","volume":"44","author":"Verougstraete","year":"2021","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib78","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/15563650.2021.1879111","article-title":"Death associated with brorphine, an emerging novel synthetic opioid","volume":"59","author":"Vohra","year":"2021","journal-title":"Clin. Toxicol. (Philos. )"},{"key":"10.1016\/j.forsciint.2023.111775_bib79","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/1556-4029.14623","article-title":"Brorphine \u2013 investigation and quantitation of a new potent synthetic opioid in forensic toxicology casework using liquid chromatography-mass spectrometry","volume":"66","author":"Krotulski","year":"2021","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.forsciint.2023.111775_bib80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/20961790.2018.1460063","article-title":"Fatalities caused by novel opioids: a review","volume":"4","author":"Drummer","year":"2018","journal-title":"Forensic Sci. Res."},{"key":"10.1016\/j.forsciint.2023.111775_bib81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1389201019666180405162734","article-title":"Analytical approaches in fatal intoxication cases involving new synthetic opioids","volume":"19","author":"Gerace","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.forsciint.2023.111775_bib82","first-page":"1","article-title":"New synthetic opioids in biological and non-biological matrices: A review of current analytical methods","volume":"102","author":"Marchei","year":"2018","journal-title":"TrAC"},{"key":"10.1016\/j.forsciint.2023.111775_bib83","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2116\/analsci.18R004","article-title":"Ten years of fentanyl-like drugs: a technical-analytical review","volume":"355","author":"Roda","year":"2019","journal-title":"Anal. Sci."},{"key":"10.1016\/j.forsciint.2023.111775_bib84","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jemermed.2017.05.034","article-title":"U-47700: a clinical review of the literature","volume":"53","author":"Rambaran","year":"2017","journal-title":"J. Emer. Med"},{"key":"10.1016\/j.forsciint.2023.111775_bib85","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.forsciint.2019.04.030","article-title":"Toxic lifespan of the synthetic opioid U-47,700 in Finland verified by re-analysis of UPLC-TOF-MS data","volume":"300","author":"Kriikku","year":"2019","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2023.111775_bib86","first-page":"158","article-title":"A fatality related to the synthetic opioid U-47700: postmortem concentration distribution","volume":"41","author":"McIntyre","year":"2017","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib87","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jat\/bku011","article-title":"A fatality involving AH-7921","volume":"38","author":"Vorce","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib88","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/dta.1984","article-title":"The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis","volume":"8","author":"Elliott","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib89","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/dta.2393","article-title":"Analysis of fentanyl analogs and novel synthetic opioids in blood, serum\/plasma, and urine in forensic casework","volume":"10","author":"Moody","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2023.111775_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2019.110137","article-title":"Development of an UPLC-MS\/MS method for the analysis of 16 synthetic opioids in segmented hair, and evaluation of the polydrug history in fentanyl analogue users","volume":"307","author":"Ram\u00edrez Fern\u00e1ndez","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2023.111775_bib91","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jat\/bky053","article-title":"Quantitative analysis of novel synthetic opioids, morphine and buprenorphine in oral fluid by LC-MS-MS","volume":"42","author":"Truver","year":"2018","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib92","first-page":"709","article-title":"Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC-MS\/MS in postmortem casework","volume":"40","author":"Mohr","year":"2016","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2023.111775_bib93","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/1467-9566.12848","article-title":"Take-home naloxone and the politics of care","volume":"41","author":"Farrugia","year":"2019","journal-title":"Sociol. Health Illn."},{"key":"10.1016\/j.forsciint.2023.111775_bib94","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","article-title":"Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids \u2013 conception and maturation","volume":"178","author":"McDonald","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.forsciint.2023.111775_bib95","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, Take-home naloxone, \u3008https:\/\/www.emcdda.europa.eu\/publications\/topic-overviews\/take-home-naloxone_en\u3009, 2022 (Accessed 16 December 2022)."},{"key":"10.1016\/j.forsciint.2023.111775_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.forsciint.2023.111775_bib97","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00213-022-06125-5","article-title":"Treatment of opioid overdose: current approaches and recent advances","volume":"239","author":"Britch","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.forsciint.2023.111775_bib98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2019.1613372","article-title":"The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs","volume":"18","author":"Kim","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.forsciint.2023.111775_bib99","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/jpet.118.256115","article-title":"Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose","volume":"371","author":"Krieter","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Forensic Science International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073823002256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073823002256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T18:14:22Z","timestamp":1759947262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0379073823002256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":91,"alternative-id":["S0379073823002256"],"URL":"https:\/\/doi.org\/10.1016\/j.forsciint.2023.111775","relation":{},"ISSN":["0379-0738"],"issn-type":[{"value":"0379-0738","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-fentanyl new synthetic opioids \u2013 An update","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.forsciint.2023.111775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111775"}}